Cyril Caldani
Agence française de sécurité sanitaire des produits de santé
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cyril Caldani.
Transfusion | 2011
Yves Ozier; Jean-Yves Muller; Paul-Michel Mertes; Philippe Renaudier; Philippe Aguilon; N. Canivet; P. Fabrigli; Danielle Rebibo; Mahdi Tazerout; Catherine Trophilme; Béatrice Willaert; Cyril Caldani
BACKGROUND: Transfusion‐related acute lung injury (TRALI) is a major cause of transfusion‐related mortality and morbidity. Epidemiologic studies using data from national transfusion schemes can help achieve a better understanding of TRALI incidence.
Transfusion | 2015
Bruno Lafeuillade; François Eb; Nadra Ounnoughene; Rachel Petermann; Gérald Daurat; Gérard Huyghe; Mai-Phuong Vo Mai; Cyril Caldani; Danielle Rebibo; Pierre Weinbreck
Regarding blood safety, transfusion‐transmitted bacterial infection (TTBI) remains the most frequent infectious risk. The incidence of these episodes needs to be assessed and updated frequently to accurately manage this risk.
Transfusion Clinique Et Biologique | 2009
P. Renaudier; D. Rebibo; C. Waller; S. Schlanger; M.P. Vo Mai; N. Ounnoughène; P. Breton; S. Cheze; A. Girard; L. Hauser; J.-F. Legras; A. Saillol; Béatrice Willaert; Cyril Caldani
Pulmonary oedemas occurring during or after a blood transfusion appear as the most frequent serious immediate incidents in the French hemovigilance database. They include transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI). TACO are a major cause of transfusion-related death in France. TRALI are more and more recognized and notified. In no case, pooled fresh frozen plasma (100 donations) treated with solvent-detergent were involved in French TRALI cases. A logigrame will allow hemovigilance officers to better classify pulmonary oedemas in e-fit, the French hemovigilance database.
Transfusion Medicine and Hemotherapy | 2008
Béatrice Willaert; Mai-Phuong Vo Mai; Cyril Caldani
The Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps; French Health Products Safety Agency) is responsible, through its hemovigilance unit, for the organization and the functioning of the national hemovigilance network. In accordance with the French law, it receives all data on adverse transfusion reactions regardless of their severity. With the aim of evaluating the tolerance of two kinds of labile blood products (LBP), pooled platelet concentrates (PP) and apheresis platelet concentrates (APC), we screened the French national database from January 1, 2000 to December 31, 2006. We observed that the number of transfusion incident reports is more than twice as high with APC (8.61:1,000 LBP) than with PP (4.21:1,000 LBP). The difference between these two ratios is statistically significant as shown by chi-square test (e = 21.00 with α= 5%). The risk to suffer adverse reactions of any type, except for alloimmunization, is higher with APC, and the major type of diagnosis related to APC is allergic reaction (1:200 APC issued) even if those allergic reactions are rarely serious. The new French National Hemovigilance Commission should impel a working group evaluating this topic and above all the impact of additive solutions which have been used since 2005 to put forward preventives measures.
Transfusion Clinique Et Biologique | 2010
Yves Ozier; Philippe Renaudier; Cyril Caldani; P. Aguilon; N. Canivet; P. Fabrigli; Paul-Michel Mertes; Jean-Yves Muller; Danielle Rebibo; M. Tazerout; C. Trophilme; Béatrice Willaert; M. Carlier
Pulmonary oedema after transfusion of blood products may be hydrostatic (transfusion-associated circulatory overload [taco]) or exsudative (transfusion-related acute lung injury [trali]). Both conditions have been recognized as major hazards to transfusion recipients. Risk characterization is necessary to improve safety and to monitor trends in the national blood transfusion system. A collaborative multidisciplinary working group of the French National Hemovigilance Committee has proposed an analysis framework for case definitions and classification. The method relies on internationally used definitions and is adapted to the codification procedures used in the french transfusion incident reports electronic data management.
Transfusion Medicine and Hemotherapy | 2008
Philippe Renaudier; Syvie Schlanger; Mai-Phuong Vo Mai; Nadra Ounnoughene; Pascal Breton; Stéphane Cheze; Albane Girard; Lisette Hauser; Jean François Legras; Hélène Odent-Malaure; Danielle Rebibo; Chantal Waller; Béatrice Willaert; Cyril Caldani
The French Hemovigilance Network has been established in 1994 and records all adverse events associated with the transfusion of a labile blood products (LBP) regardless of their severity. From 1994 to 2006 35,423,172 LBP were issued, 85,812 adverse transfusion reactions notified, and 139 cases of transfusion related acute lung injury (TRALI) observed. The LBP most at risk is fresh frozen plasma (FFP), followed by platelets concentrates (PC) and packed red cells (PRC). However, because the use of FFP is not frequent in France, it only accounts for about 10% of TRALI, whereas PRC and PC are involved in the remaining cases. In no case, pooled FFP treated with solvent-detergent were involved. Patients’ profiles are peculiar with a high disease burden. Therefore, targeting a prevention policy only on FFP would result in a marginal reduction of TRALI in France.
Transfusion Clinique Et Biologique | 2012
Yves Ozier; F. Mouquet; Claire Rieux; Paul-Michel Mertes; Jean-Yves Muller; Cyril Caldani; Karim Boudjedir; M. Carlier
A working group of the French National Hemovigilance Committee has been in charge of heightening awareness of Transfusion-Associated Circulatory Overload (TACO) among physicians and nurses. This multidisciplinary group has produced the present document that focuses on epidemiological data provided by the French haemovigilance network, physiopathology, diagnosis, treatment and specific actions that could prevent or minimize the risk of TACO.
Transfusion Medicine and Hemotherapy | 2008
Hans-Gert Heuft; Wolfgang Mende; Rainer Blasczyk; Franz Weinauer; Béatrice Willaert; Mai-Phuong Vo Mai; Cyril Caldani; Philippe Renaudier; Syvie Schlanger; Nadra Ounnoughene; Pascal Breton; Stéphane Cheze; Albane Girard; Lisette Hauser; Jean François Legras; Hélène Odent-Malaure; Danielle Rebibo; Chantal Waller; Catherine E. Chapman; Lorna M. Williamson; Markus Jutzi; Guy Levy; Behrouz Mansouri Taleghani; Peter Hellstern; Walter E. Hitzler; Britta Engelhardt; Mark A. Popovsky; Matthias Hecker; Hans-Dieter Walmrath; Werner Seeger
Service
The Journal of Allergy and Clinical Immunology | 2012
Paul-Michel Mertes; P. Demoly; Annick Alpérovitch; A. Bazin; Jacques Bienvenu; Cyril Caldani; Bernard Lamy; Dominique Laroche; Marie-Françoise Leconte des Floris; Jean-Yves Py; Danielle Rebibo; Béatrice Willaert; Christian Drouet; M. Carlier; André Lienhart
Blood | 2006
Philippe Renaudier; Mai Phuong Vo Mai; Nadra Ounnoughene; Béatrice Willaert; Cyril Caldani
Collaboration
Dive into the Cyril Caldani's collaboration.
Agence française de sécurité sanitaire des produits de santé
View shared research outputsAgence française de sécurité sanitaire des produits de santé
View shared research outputsAgence française de sécurité sanitaire des produits de santé
View shared research outputsAgence française de sécurité sanitaire des produits de santé
View shared research outputsAgence française de sécurité sanitaire des produits de santé
View shared research outputsAgence française de sécurité sanitaire des produits de santé
View shared research outputsAgence française de sécurité sanitaire des produits de santé
View shared research outputs